海泰科(301022.SZ):年產15萬噸高分子新材料項目目前處於建設期,預計2025年下半年開始試生產
格隆匯11月26日丨海泰科(301022.SZ)於近期投資者關係活動表示,年產15萬噸高分子新材料項目目前處於建設期,預計2025年下半年開始試生產。該項目的目標客户主要以現有客户為主,同時兼顧開拓新客户,消化本次募投項目產能。本次募投項目目前已積累了部分意向客户,並與部分目標客户簽署了框架合作協議。項目完全達產後預計平均每年實現銷售收入174,500.00萬元,淨利潤7,368.15萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.